A Phase 1 Study to Evaluate the Effect of BCX7353 on the Single Dose Pharmacokinetics of the P-gp Substrate Digoxin and the BCRP Substrate Rosuvastatin and the Effect of the P-gp Inhibitor Cyclosporine on the Single Dose Pharmacokinetics of BCX7353

Trial Profile

A Phase 1 Study to Evaluate the Effect of BCX7353 on the Single Dose Pharmacokinetics of the P-gp Substrate Digoxin and the BCRP Substrate Rosuvastatin and the Effect of the P-gp Inhibitor Cyclosporine on the Single Dose Pharmacokinetics of BCX7353

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs BCX 7353 (Primary) ; Ciclosporin; Digoxin; Rosuvastatin
  • Indications Hereditary angioedema
  • Focus Pharmacokinetics
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 24 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 04 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top